D
DROIA
Venture CapitalActiveDROIA is a specialist investor, exclusively focused on the development of oncology therapies.
14
Investments
1
Exits
—
AUM
7.1%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for DROIA.
Investment Thesis & Strategy
DROIA invests in various stages of oncology therapy companies, seeking to support the development of innovative treatments in the healthcare sector.
Investment Activity
Deals per year over the last 5 years
2
20180
20191
20201
20214
2022Portfolio Companies
Selected investments from their portfolio of 14 companies
C
Cellares
Biotech · Growth, 2022
N
NextPoint Therapeutics
Biotech · Series A, 2022
R
Rgenta Therapeutics
Biotech · Series A, 2022
T
T-knife Therapeutics
Biotech · Series B, 2022
A
Affini-T Therapeutics
Biotech · Series A, 2021
T
Triumvira Immunologics
Biotech · Series A, 2020
P
Pliant Therapeutics
Biotech · Series B, 2018
I
Immatics
Biotech · Growth, 2018
Frequently Asked Questions
DROIA focuses on Series A, Series B, Series C+ stage investments.
Related Investors
Cipio Partners
Luxembourg, Luxembourg · 76 deals
Adara Ventures
Luxembourg, Luxembourg · 45 deals
Redline Capital
Luxembourg, Luxembourg · 34 deals
La Maison ITF
Luxembourg, Luxembourg · 29 deals
La Maison Compagnie d'Investissement
Luxembourg, Luxembourg · 23 deals
Insitor Partners
Luxembourg, Luxembourg · 16 deals